Advertisement

Topics

TERUFLEX® BLOOD BAG SYSTEMCPDA-1 SOLUTION | TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1) [Terumo Corporation] | BioPortfolio

12:25 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

For the collection of 250 mL of Whole Blood

Revised 2015-12 N-BB-A 3

FULL PRESCRIBING INFORMATION*Sections or subsections omitted from the Full Prescribing Information are not listed [includes sections 4, 6, 7, 8, 9, 10, 12, 13, 14, 15 and 17]. 1.   INDICATIONS AND USAGE 1.1.   Read these instructions carefully before use. 1.2.   Rx ONLY.1.3.   Intended for the collection, processing and preservation of Whole Blood and blood components. Not intended for direct intravenous infusion.1.4.   For the collection of 250 mL ±10% Whole Blood:    1.4.1.    From elderly, pediatric, or smaller autologous donors who may not tolerate larger blood collections.    1.4.2.    For blood collections as directed by a patient's physician.1.5.   NOTE: Production of Platelets and Plasma is not intended with this product.

2.   DOSAGE AND ADMINISTRATION

2.1.      To open blister package, peel cover film back 4/5 of its length.

2.2.      Prepare the blood bag following your institution's standard operating procedures.

2.3.      Make a loose knot in the donor tubing approximately 10 cm or 4 inches from the needle unless alternate methods are used to seal the tubing at the end of collection.

2.4.      Temporarily clamp donor tubing.

2.5.      Suspend the collection bag as far as possible below the donor's arm.

2.6.      Apply blood pressure cuff or tourniquet to donor's arm. Disinfect site of phlebotomy according to institutional standard operating procedures. If blood pressure cuff is used, inflate to approximately 60 mmHg.

2.7.      Remove the needle cover and perform phlebotomy.

    2.7.1.   CAUTION:   Do not touch the needle after removing the needle cover.

2.8.      Remove the temporary clamp on the donor tubing to permit blood flow into the collection bag.

2.9.    Secure donor tubing to donor's arm.

2.10.   Mix blood with anticoagulant in the collection bag and continue to mix at several intervals during collection and immediately after collection. If using an automated mixer, follow manufacturer's instructions.

2.11.   Collect labeled volume of blood 250 mL ±10%.

2.12.   When the desired amount of blood has been collected, seal the tubing or tighten the loose knot (white knot) prepared in Step 2.3. Temporarily clamp between the knot and needle. Sever donor tubing between knot and clamp. Alternate methods may be used to seal tubing. Collect blood samples using careful attention to aseptic technique and following your institution's standard operating procedures.

2.12.1. CAUTION: Do not use a dielectric tube sealer to seal the tubing while the needle is connected to the donor's body unless it is approved for such a purpose.

2.13.   Reapply clamp to donor tubing; release pressure on donor's arm and remove needle. If using a needle safety device, follow manufacturer's instructions.

2.13.1.   CAUTION: Discard phlebotomy needle/donor tubing according to institutional standard operating procedures.

2.14.   Immediately after collection, invert collection bag several times to assure blood and anticoagulant are well mixed.

2.15.   Strip blood from donor tubing into collection bag, mix well, and allow tubing to refill; repeat once. To prevent the blood from clotting in the tubing, work quickly as possible. Make an appropriate number of segments of anticoagulated blood for testing by sealing on or near the X marks. Leave segments attached to Whole Blood unit.

2.16.   Store CPDA-1 Whole Blood (or Red Blood Cells) between 1 – 6 ° C for up to 35 days.

2.17.   For further preparation and processing of other components, use standard processing and storage techniques following approved regulations and standards.

    2.17.1.   NOTE: Production of Platelets and Plasma is not intended with this product.

3.   DOSAGE FORMS AND STRENGTHS

3.1.   35 mL Citrate Phosphate Dextrose Adenine (CPDA-1) anticoagulant USP for collection of 250 mL Whole Blood. Each 35 mL contains 105mg Citric Acid (anhydrous) USP, 921mg Sodium Citrate (dihydrate) USP, 77.7mg Monobasic Sodium Phosphate (monohydrate) USP, 1.12g Dextrose (monohydrate) USP and 9.63mg Adenine USP.

5.   WARNINGS AND PRECAUTIONS

5.1.   Rx ONLY.

5.2.   Do not use unless solutions are clear and free from particulates.

5.3.   Always inspect the blood bag set for leaks before use.

5.4.   Avoid excessive heat and direct sunlight. Protect from freezing.

5.5.   Recommended storage conditions: Room Temperature (15-30°C/59-86°F).

5.6.   It is normal to have condensation in the blister packaging. If the amount of moisture is greater than expected, check for leaks from the fluid-filled components of the blood bag set.

5.7.   Use aseptic techniques.

5.8.   Do not use a dielectric tube sealer to seal the tubing while the needle is connected to the donor's body unless it is approved for such a purpose.

5.9.   Do not touch needle after removing the needle cover.

5.10. Discard phlebotomy needle/donor tubing according to institutional standard operating procedures.

5.11. The AGELESS® (oxygen absorber packet, Mitsubishi Gas Chemical) contained in this package absorbs oxygen and generates heat on removal. Do not open and handle it with care.

5.12. Dispose of the AGELESS packet with the blister tray.

5.13. Do not dispose the AGELESS packet with wastes containing volatile or flammable materials.

5.14. Due to possible exposure to infectious agents in the handling of blood, take adequate precautions at all times to prevent exposure to and transmission of such agents. Follow your institution's standard operating procedures.

11.   DESCRIPTION

11.1.   This blood bag system includes a 16 gauge x 1 1/2 inch (1.60 x 38 mm) needle with needle cover and a 250 mL (nominal capacity 300 mL) collection bag containing 35 mL Citrate Phosphate Dextrose Adenine (CPDA-1) anticoagulant.

11.2.   The blood bag collection set is made of PVC (polyvinyl chloride with DEHP plasticizer).

11.3.   The blood bag has no components made of natural rubber latex.

11.4.   Tubing internal diameter (ID) nominal 3.0 mm.

11.5.   Tubing outer diameter (OD) nominal 4.4 mm.

11.6.   Donor tubing line maximum 12 segments available.

16.   HOW SUPPLIED/STORAGE AND HANDLING

16.1.   Single use only.

16.2.   Sterile and non-pyrogenic fluid path. Sterilized by steam. Opacity of the blood bag system may be observed. This is due to moisture absorption during the sterilization process. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

16.3.   A Material Safety Data Sheet (MSDS) is not required for this product.

16.4.   Recommended storage conditions: Room Temperature (15-30°C/59-86°F).

16.5.   Avoid excessive heat and direct sunlight. Protect from freezing.

16.6.   To open blister package, peel cover film back 4/5 of its length.

16.7.   After opening the blister package, unused blood bags may be stored at room temperature for 96 hours or they may be stored for 30 days by returning cover film to original position and sealing with tape to prevent evaporation of solutions.

16.8.   Blood bags in the unopened blister package may be used through the last day of the month and year as indicated on the original manufacturer's packaging.

16.9.   The AGELESS packet contained in this package absorbs oxygen and generates heat on removal. Do not open and handle it with care.

16.10.  Dispose of the AGELESS packet with the blister tray.

16.11.  Do not dispose the AGELESS packet with wastes containing volatile or flammable materials.

16.12.  The Single blood bag set, Code BB*SCD256A, is supplied 90/case.

MANUFACTURED BY: TERUMO CORPORATION 44-1, 2-CHOME, HATAGAYA, SHIBUYA-KU, TOKYO 151-0072, JAPAN MADE IN JAPAN(R): Registered Trademark ©TERUMO CORPORATION December, 2015

AGELESS is a registered trademark of MITSUBISHI GAS CHEMICAL CO., INC.

Tray/Case LabelTERUFLEX® BLOOD BAG SYSTEM ANTICOAGULANT CITRATE PHOSPHATEDEXTROSE ADENINE SOLUTION (CPDA-1) USPFOR COLLECTION OF 250mL OF BLOOD Each unit consists of a primary bag containing 35 mL of solution with105 mg Citric Acid (anhydrous) USP, 921 mg Sodium Citrate (dihydrate)USP, 77.7 mg Monobasic Sodium Phosphate (monohydrate) USP, 1.12 gDextrose (monohydrate) USP, 9.63 mg Adenine USP. STERILE, NON-PYROGENIC FLUID PATH.DO NOT USE UNLESS ANTICOAGULANT IS CLEAR CODELOT No.EXPIRYUNIT(S)DONOR NEEDLE 16G X 1 1/2˝ (1.60 X 38mm)Rx ONLYRECOMMENDED STORAGE: Room Temperature (15-30°C/59-86°F).Avoid excessive heat. Protect from freezing. After opening, unused bags may be stored at room temperature for 96 hours, or they may bestored for 30 days in the blister package after returning the cover film to original position andsealing with tape to prevent possible loss of moisture. See Instructions For Blood Collection Manufactured by : TERUMO CORPORATION Tokyo, Japan® : Registered TrademarkIssued 2009 -10

Image of Label:

Manufacturer

Terumo Corporation

Active Ingredients

Source

Drugs and Medications [683 Associated Drugs and Medications listed on BioPortfolio]

Cpda-1 [fenwal, inc.]

Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1) Blood-Pack Unit

Cpda-1 [fenwal, inc.]

Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1) BLOOD-PACK™ Unit

Cpda-1 [fenwal, inc.]

Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1) BLOOD-PACK™ Unit

Cpda-1 [fenwal, inc.]

Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1) BLOOD-PACK™ Unit

Cpda-1 [fenwal, inc.]

Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1) BLOOD-PACK™ Unit

Clinical Trials [9814 Associated Clinical Trials listed on BioPortfolio]

Exposure of Salvaged Blood to Inflammation and Oxidative Stress: the Effect of Different Anticoagulant Regimes (HECICS)

The primary aim of this randomized controlled study is to determine whether the use Anticoagulant Citrate Dextrose Solution--Formula A (ACD-A) in cell salvage reduces inflammation and oxid...

The Effect of Citrate Dialysate on Clot Formation and Anemia in Hemodialysis Patients

Acetate-free citrate containing dialysate is expected to be clinically effective in maintaining hemodynamic stability during hemodialysis (HD). It has been demonstrated that citrate dialys...

40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose

The aim of this study was to evaluate the safe of 40% Dextrose oral administration on blood glucose concentration and to reducing of pain before painful procedures on healthy term neonate ...

A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

This is a research study for people with high blood phosphorus levels who are on dialysis. This medical condition can cause weakening of the bones and damage other organs. This can lead t...

A Study of Ferric Citrate to Improve Inflammation and Lipid Levels

The risk of cardiovascular mortality in patients with end stage renal disease on hemodialysis is 10-100 times higher than the normal population. This is due in part to high levels of infla...

PubMed Articles [16292 Associated PubMed Articles listed on BioPortfolio]

Haematological and morphological evaluation of feline whole blood units collected for transfusion purposes.

Objectives Despite the increasing availability of feline blood collected and stored for transfusion purposes, few studies have been performed on feline blood units. The aim of this prospective in vitr...

Sodium citrate contributes to the platelet storage lesion.

Sodium citrate has become the preferred anticoagulant used for apheresis collection and has been included in commercial platelet additive solutions (PASs) since PAS-II. It was suggested that citrate b...

An In Vitro Blood Flow Loop System for Evaluating the Thrombogenicity of Medical Devices and Biomaterials.

A reliable in vitro dynamic test method to evaluate device thrombogenicity is very important for the improvement of the design and safety of blood-contacting medical devices, while reducing the use of...

Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.

The phosphaturic hormone FGF23 is elevated in chronic kidney disease (CKD). The risk of premature death is substantially higher in the CKD patient population, with cardiovascular disease (CVD) as the ...

Photogeneration of hydroxyl radical in Fe(III)-citrate-oxalate system for the degradation of fluconazole: mechanism and products.

The photochemical role of Fe(III)-citrate complex is significant in natural waters due to its ubiquitous existence and excellent photoreactivity at near neutral pH. Although there are many reports on ...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record